Systemic Lupus Erythematosus Resource Center

Chandra Mohan, MD, PhD, provided an update on the immunology behind SLE and research findings from the past decade.... [Read More]

ACR CONVERGENCE 2020—Rheumatologists and patients have struggled with a lack of new therapies for systemic lupus erythematosus (SLE), but a better understanding of the underlying mechanisms behind the disease helps shed light on potential treatments. That was the theme of the ACR Convergence session State of the Art: Lupus—The Future Is Now, led by Peggy… [Read More]

ACR CONVERGENCE 2020—Held Nov. 5–9, the ACR’s first fully virtual annual meeting is a wrap, but that doesn’t mean it’s too late to catch the highlights. Dozens of research abstracts on various aspects of lupus were presented during the fully virtual event, and David S. Pisetsky, MD, PhD, professor of medicine and immunology at Duke… [Read More]

Early results in a phase 2 trial are finding that adding a TNF blocker to other treatment could greatly lower the risk of serious complications during pregnancy for women who have antiphospholipid syndrome with lupus anticoagulant.... [Read More]

ACR CONVERGENCE 2020—The definition of cell type depends increasingly on a cell’s molecular features. On Friday, Nov. 6, 2020, Alex Kuo, PhD, senior scientist at Stanford University School of Medicine, Stanford, Calif., described six technologies that are relatively mature and can be used for rheumatic disease research: Rapidly developing single-cell RNA sequencing (scRNA-seq); Cellular indexing… [Read More]

ACR CONVERGENCE 2020—New evidence, though derived from small numbers, suggest that treatment with the TNF-inhibitor certolizumab could help improve high-risk pregnancy outcomes in women with antiphospholipid syndrome (with or without systemic lupus erythematosus) and lupus anticoagulants, an expert said. In the Phase 2 IMPACT trial, which has already enrolled 27 women and is continuing to… [Read More]

ACR CONVERGENCE 2020—With an understanding of the key causes that are behind immune abnormalities in systemic lupus erythematosus (SLE), rheumatologists gain insights into this disease. During the ACR Convergence session Immunology Update—The Decade in Review: 10 Steps to SLE, Chandra Mohan, MD, PhD, Hugh Roy and Lillie Cranz Cullen Endowed Professor, University of Houston, provided… [Read More]

ACR CONVERGENCE 2020—Although rheumatologists have struggled with a lack of new therapies for systemic lupus erythematosus (SLE), recent positive trial results have brought renewed hope for more treatments. That was the theme of the ACR Convergence 2020 session, State of the Art: Lupus—The Future Is Now, led by Peggy Crow, MD, the Benjamin M. Cohen… [Read More]

ACR CONVERGENCE 2020—At the annual meeting’s second Plenary Session, Saturday, Nov. 7, speakers highlighted phase 2 results of a potential new biologic for systemic lupus erythematosus (SLE), as well as data on remission maintenance in rheumatoid arthritis (RA) after withdrawal of etanercept or methotrexate. Phase 2 Trial of Monoclonal Antibody for Lupus (LILAC) Several converging… [Read More]

ACR CONVERGENCE 2020—The ACR’s first fully virtual annual meeting kicked off on Thursday, Nov. 5. During the Opening Session, ACR President Ellen M. Gravallese, MD, talked about how the specialty’s response during the pandemic has provided great hope and will help rheumatology become an even more essential specialty. At the first Plenary Session on Friday,… [Read More]